Apogee Therapeutics secured up to $1.3 billion in financing from Blackstone Life Sciences to fund Phase 3 development and potential commercialization of its long-acting atopic dermatitis therapy zumilokibart. The structure is designed to support large, capital-intensive late-stage work while extending the company’s runway. Apogee’s Phase 3 push follows renewed scrutiny of how advanced biologics and long-acting mechanisms compete against dermatology incumbents, including dupilumab and emerging competitors. The financing underscores investor appetite for differentiation where trial readouts can de-risk both efficacy durability and dosing convenience. For the sector, the deal is a signal that large-scale private capital is increasingly substituting for traditional funding in moments when public-market windows remain selective—particularly for late-stage dermatology programs.